ANALISIS EFEKTIVITAS BIAYA ARIPRIPRAZOL DENGAN OLANZAPIN PADA PASIEN RAWAT INAP SKIZOFRENIA DI RUANG TENANG RSKD DUREN SAWIT

Authors

Tri Murtini a:1:{s:5:"en_US";s:8:"Personal";}
Yusi Anggriani Dosen Universitas Pancasila Jakarta
Fredrik Dermawan Purba Dosen Universitas Padjajaran Bandung

Keywords:

Kata kunci : analisis efektivitas biaya, skizofrenia, aripriprazol, olanzapine, fase tenang, analisis efektivitas biaya, skizofrenia, aripriprazol, olanzapine, fase tenang

Abstract

Masalah kesehatan jiwa di Indonesia merupakan masalah kesehatan yang sangat penting dan harus mendapatkan perhatian yang serius. Terapi pasien skizofrenia di ruang tenang dapat diberikan obat Olanzapin (generik), Aririprazol (Abilify®) dan Olanzapin (Sopavel®). Harga Aripriprazol (Abilify®) lebih mahal dari Olanzapin generik dan Olanzapin (Sopavel®). Penelitian ini bertujuan melihat efektivitas biaya. Desain penelitian adalah kohort, pengambilan sampel dilakukan dengan total sampling dan dilaksanakan pada bulan Juni – September 2019 di ruang tenang RSKD Duren Sawit. Data diambil dari rekam medis yang meliputi skor PANSS awal dan akhir, biaya total medis langsung. Total sampel yang diperoleh dari penelitian ini adalah 206 pasien yang terdiri dari 30 pasien kelompok aripriprazol (abilify®), 62 pasien kelompok olanzapin generik dan 114 pasien kelompok olanzapin (sopavel®). Rerata biaya total medis langsung aripriprazol (abilify®) adalah Rp 1.748.652,07 lebih tinggi dibandingkan olanzapin generik seharga Rp 1.430.129,79 dan olanzapin (sopavel®) Rp 1.718.436,68. Hasil uji pre dan post terapi menunjukkan perbedaan bermakna untuk penurunan skor PANSS. Uji beda ketiga terapi dengan uji statistik Kruiskall Wallis menunjukkan perbedaan bermakna (p=0,006,P<0,05) untuk rerata penurunan skor PANSS, aripriprazol(abilify®) 45,43, Olanzapin 26,48 dan Sopavel® 44,55. Akan tetapi tidak menunjukkan perbedaan bermakna (p>0,005)terhadap lama hari rawat (LOS)

References

Pemerintah Indonesia. Undang Undang RI Nomor 18 Tahun 2014 Tentang Kesehatan Jiwa. Jakarta; 2014

Kementerian Kesehatan RI. Hasil Utama Riskesdas 2018. Jakarta; 2018. h 79-77.

Pengurus Pusat Perhimpunan Dokter Spesialis Kedokteran Jiwa. Pedoman Nasional PelayananKedokteran Jiwa/Psikiatri. Jakarta; 2012.

BPJS Kesehatan. Info BPJS Kesehatan: Penderita skizofrenia bisa mendapat pelayanan kesehatan melalui JKN-KIS. Jakarta; Media External BPJS; 2017. H 14-15.

Dinas Komunikasi, Informasi dan Statistik Pemprov DKI Jakarta. Rumah Sakit Khusus Daerah Duren Sawit [ Internet]. 1 Januari 2017 [ diakses 12 Maret 2019 ]. Diakses dari: https://jakarta.go.id/artikel/konten/1189/duren-sawit-rumah-sakit-khusus-daerah

Syarif A., Gayatri A., Estiningsih A., Setiawati A., Muhtar A., Arif A., et al. Farmakologi dan Terapi. Edisi VI. Jakarta; Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia; 2016, h 165-171.

Andayani TM., Farmakoekonomi Prinsip dan Metodologi. Yogyakarta; Bursa Ilmu; 2013.

Kementerian Kesehatan RI. Pedoman Penerapan Kajian Farmakoekonomi. Jakarta; 2013.

Nurmiati A. Pengenalan Instrumen PANSS. Jakarta. Fakultas Kedokteran Universitas Indonesia; 2008.

Haya A.S., Peng X., Faries DE., Stauffer VL., Kane L. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion. 2011; Vol 27.

Zahnia S, Sumekar DW. Kajian Epidemiologis Skizofrenia. Lampung; Majority; 2016; 5 (4);160-166.

Robert D Mc Quade, Elyse S., Ron M., et all,. A Comparison of Weight Change During treatment With Olanzapine or Aripriprazol: Result from a Randomized, double-blind Study. The journal of clinical psychiatry, 65 (supply18). 47-48.

Kane JM., Osuntokn O., Kryzhanovskaya LA., Xu W., Satuffer VL., Watson SB., Breier A.,. A 28-week, randomized, double-blind study of olanzapine versus aripriprazol in the treatmenr of scizofrenia., The jounal of Clinical psychiatry. 2009.70(4) 572-581.

Hong E., MD., Hypokalmia and Phychosis : A Forgotten Association, the American journal of phychiatry Residents Journal; 2017;10(1176); 6-7.

Chrzanowki WK., Marcus RN., Torbeyns A., Nyilas M., McQuade RD. Effectiveness of long-term aripriprazole therapy in patients with acutly relapsing or chronic, stable schizophrenia: a 52-week, open label comparison with olanzapune. Psychopharmacology.2006. Vol 189. Issue 2.pp 259-266.

Leucht S., Kane M. Jane,Kissling W, Hamann J., Etschel E., Engel R., What Does the PANSS Means: Vol79, p23

Downloads

Published

2022-12-30

Issue

Vol. 26 No. 3 (2022): MFF

Section

Articles

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The copyright to this article is transferred to Universitas Hasanuddin (UNHAS) if and when the article is accepted for publication. The undersigned hereby transfers all rights in and to the paper including without limitation all copyrights to UNHAS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment.

We declare that:

This paper has not been published in the same form elsewhere.
It will not be submitted anywhere else for publication prior to acceptance/rejection by this Journal.
A copyright permission is obtained for materials published elsewhere and which require this permission for reproduction.

Furthermore, I/We hereby transfer the unlimited rights of publication of the above-mentioned paper in whole to UNHAS The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online) or any other reproductions of similar nature.

The corresponding author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. This agreement is to be signed by at least one of the authors who have obtained the assent of the co-author(s) where applicable. After submission of this agreement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted.